A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

计划入组 45 人 · 首次发布于 2023 年 10 月 27 日

Study to Evaluate D-1553 in Subjects With Lung Cancer

计划入组 225 人 · 首次发布于 2022 年 5 月 20 日

Study to Evaluate D-1553 in Subjects With Solid Tumors

计划入组 180 人 · 首次发布于 2020 年 10 月 14 日

Garsorasib(安方宁)

TAS-1553

Anabio R&D

Vietnam

Vitamin D Society

Canada

Wolinsky, Fredric D

United States

Garsorasib Shows 45.5% Response Rate in KRAS G12C-Mutated Pancreatic Cancer Patients

Ifebemtinib Plus Garsorasib Shows 82% ORR and 22-Month PFS in First-Line KRAS G12C-Mutant NSCLC

Adagrasib Demonstrates Superior Efficacy Over Docetaxel in KRAS G12C-Mutated NSCLC